About Interferon gamma receptor 1
Interferon gamma receptor 1 (IFNGR1) is a protein
from Homo sapiens identified by UniProt accession
P15260, 489 residues long.
MolForge cross-references it against 0 known binders and
534 disease associations.
Target properties
| Protein name | Interferon gamma receptor 1 |
| UniProt accession | P15260 |
| Gene | IFNGR1 |
| Organism | Homo sapiens |
| Length | 489 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (534)
Diseases linked to this target (Open Targets).
- disseminated atypical mycobacterial infection · score 0.54
- chronic granulomatous disease · score 0.47
- mycobacterial infectious disease · score 0.46
- osteopetrosis · score 0.44
- neoplasm · score 0.42
- tuberculosis · score 0.42
- Friedreich ataxia · score 0.36
- neurodegenerative disease · score 0.35
- idiopathic pulmonary fibrosis · score 0.34
- pulmonary fibrosis · score 0.29
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P15260-F1 | alphafold | PREDICTED | 66.01 | — |
Amino-acid sequence (489 residues)
MALLFLLPLV MQGVSRAEMG TADLGPSSVP TPTNVTIESY NMNPIVYWEY QIMPQVPVFT VEVKNYGVKN SEWIDACINI SHHYCNISDH VGDPSNSLWV RVKARVGQKE SAYAKSEEFA VCRDGKIGPP KLDIRKEEKQ IMIDIFHPSV FVNGDEQEVD YDPETTCYIR VYNVYVRMNG SEIQYKILTQ KEDDCDEIQC QLAIPVSSLN SQYCVSAEGV LHVWGVTTEK SKEVCITIFN SSIKGSLWIP VVAALLLFLV LSLVFICFYI KKINPLKEKS IILPKSLISV VRSATLETKP ESKYVSLITS YQPFSLEKEV VCEEPLSPAT VPGMHTEDNP GKVEHTEELS SITEVVTTEE NIPDVVPGSH LTPIERESSS PLSSNQSEPG SIALNSYHSR NCSESDHSRN GFDTDSSCLE SHSSLSDSEF PPNNKGEIKT EGQELITVIK APTSFGYDKP HVLVDLLVDD SGKESLIGYR PTEDSKEFS
Explore Interferon gamma receptor 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets